基于肿瘤及肿瘤生物环境的CT影像组学特征预测局部晚期非小细胞肺癌同步放化疗患者的长期生存
本研究纳入298例接受根治性同步放化疗的局部晚期非小细胞肺癌患者,按2:1随机分为训练集和验证集,利用支持向量机结合遗传算法从治疗前CT提取的肿瘤及肿瘤生物环境影像组学特征预测3年总生存。训练集和验证集AUC分别为0.965和0.869,低风险组3年OS为68.4%对高风险组3.3%(p<0.001),低风险组FEV1/FVC%、淋巴细胞减少恢复及肿瘤缓解更优。
要点
- 治疗前CT影像组学特征可预测局部晚期NSCLC同步放化疗后的3年总生存。
- 低风险组3年OS为68.4%,高风险组为3.3%,差异有统计学意义(p<0.001)。
- 低风险组≥3级淋巴细胞减少发生率更低(63.2%对83.3%,p=0.031)。
核心结论
- 治疗前肿瘤及肿瘤生物环境的影像组学特征可提升局部晚期非小细胞肺癌长期生存预测的准确性,预测结果可作为生存风险分层的有效指标。
- 低风险患者可能从根治性同步放化疗及后续辅助免疫治疗中获益更多。
研究设计与样本
- 共纳入298例符合条件的局部晚期非小细胞肺癌患者,按2:1随机分为训练集和验证集。
- 采用支持向量机结合遗传算法的集成特征选择与模型训练方法,预测3年总生存。
- 根据预测的生存状态将患者分为高风险组和低风险组。
- 采集肺功能检测和血气分析指标并与影像组学特征关联,记录同步放化疗前后外周血淋巴细胞计数的动态变化。
- 试验注册为回顾性注册。
主要发现
- 预测模型共筛选出9个特征,包括5个肿瘤相关特征和4个肺部特征。
- 训练集和验证集的受试者工作特征曲线下面积分别为0.965和0.869;排除所有肺部特征后分别降低0.179和0.223。
- 低风险组3年总生存优于高风险组(68.4%对3.3%,p<0.001)。
- 低风险组基线FEV1/FVC%优于高风险组(96.3%对85.9%,p=0.046)。
- 低风险组同步放化疗期间≥3级淋巴细胞减少发生率低于高风险组(63.2%对83.3%,p=0.031),淋巴细胞减少恢复率高于高风险组(71.4%对27.8%,p<0.001),≥2级放射性肺炎发生率低于高风险组(31.6%对53.3%,p=0.040),肿瘤缓解率高于高风险组(84.2%对66.7%,p=0.003)。
临床怎么用
- 原文结论认为,基于影像组学的预测结果可作为局部晚期非小细胞肺癌生存风险分层的有效指标。
- 原文结论认为,低风险患者可能从根治性同步放化疗及后续辅助免疫治疗中获益更多。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Definitive concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced non-small cell lung cancer (LANSCLC) patients, but the treatment response and survival outcomes varied among these patients. We aimed to identify pretreatment computed tomography-based radiomics features extracted from tumor and tumor organismal environment (TOE) for long-term survival prediction in these patients treated with CCRT. METHODS: A total of 298 eligible patients were randomly assigned into the training cohort and validation cohort with a ratio 2:1. An integrated feature selection and model training approach using support vector machine combined with genetic algorithm was performed to predict 3-year overall survival (OS). Patients were stratified into the high-risk and low-risk group based on the predicted survival status. Pulmonary function test and blood gas analysis indicators were associated with radiomic features. Dynamic changes of peripheral blood lymphocytes counts before and after CCRT had been documented. RESULTS: Nine features including 5 tumor-related features and 4 pulmonary features were selected in the predictive model. The areas under the receiver operating characteristic curve for the training and validation cohort were 0.965 and 0.869, and were reduced by 0.179 and 0.223 when all pulmonary features were excluded. Based on radiomics-derived stratification, the low-risk group yielded better 3-year OS (68.4% vs. 3.3%, p < 0.001) than the high-risk group. Patients in the low-risk group had better baseline FEV1/FVC% (96.3% vs. 85.9%, p = 0.046), less Grade ≥ 3 lymphopenia during CCRT (63.2% vs. 83.3%, p = 0.031), better recovery of lymphopenia from CCRT (71.4% vs. 27.8%, p < 0.001), lower incidence of Grade ≥ 2 radiation-induced pneumonitis (31.6% vs. 53.3%, p = 0.040), superior tumor remission (84.2% vs. 66.7%, p = 0.003). CONCLUSION: Pretreatment radiomics features from tumor and TOE could boost the long-term survival forecast accuracy in LANSCLC patients, and the predictive results could be utilized as an effective indicator for survival risk stratification. Low-risk patients might benefit more from radical CCRT and further adjuvant immunotherapy. TRIAL REGISTRATION: retrospectively registered.
引用
- Chen NB, Xiong M, Zhou R, et al. CT radiomics-based long-term survival prediction for locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy using features from tumor and tumor organismal environment. Radiat Oncol. 2022. PMID: 36384755. doi:10.1186/s13014-022-02136-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。